drugset
drugset / Trial / NCT04725136

Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis

NCT04725136 ↗

Phase 1/2 Unknown 96 enrolled Kang Stem Biotech Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase I/IIa Clinical Trial to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic Dermatitis

Timeline

Start
2021-01-27
Primary completion
2023-01-31
Completion
2023-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject FURESTEM-AD Inj. Cell therapy 5e+07 cells Subcutaneous
Subject FURESTEM-AD Inj. Cell therapy 1e+08 cells Subcutaneous

Indications

atopic eczema